Identity vs. purity vs. quantity testing comes down to three different questions about a peptide sample. Identity asks: is this the right molecule? Purity asks: how much of what is detected is that molecule, rather than related impurities? Quantity (also called assay or content) asks: how much of the peptide is actually present? A sample can pass one test and fail another, so no single result tells the whole story. This guide explains each test, the methods behind it, and how they fit together.
Key Takeaways
- International guidance on analytical validation treats identity, impurity (purity), and assay (content or potency) as separate categories of testing [1].
- Identity tests must identify a molecule based on unique aspects of its structure [1]. For synthetic peptides, the EMA recommends at least two orthogonal methods [2].
- Purity focuses on peptide-related impurities such as deletion sequences, insertion sequences, stereoisomers, and degradation products [2].
- Quantity (assay or content) measures how much peptide is present, using a reference standard or methods such as amino acid analysis [2].
- Synthetic peptide powders can contain water and counter-ions, so "99% pure" does not mean "99% peptide by weight" [2].
Why Three Separate Questions?
Picture a bag labeled "100 almonds". You could ask three separate things:
- Identity: Are these actually almonds?
- Purity: Of the nuts in the bag, how many are almonds rather than broken pieces or other nuts?
- Quantity: How many almonds are really in the bag, and how much of the weight is packaging or moisture?
Peptide testing works the same way. The ICH Q2(R2) guideline on validation of analytical procedures, developed through the International Council for Harmonisation, organizes tests into these same broad categories: identity, impurity (purity), and assay (content or potency). Each has its own validation requirements [1].
Identity Testing: Is It the Right Molecule?
What it answers
Identity testing confirms that the material is the intended peptide, with the correct sequence, and not a similar-looking molecule.
How it is done
ICH Q2(R2) explains that identification tests must be able to identify the analyte based on unique aspects of its molecular structure. They are confirmed by positive results for samples containing the analyte and negative results for samples that do not, including closely related materials [1].
For synthetic peptides, the European Medicines Agency (EMA) recommends using at least two orthogonal methods for identification. Suitable options include [2]:
- molecular mass by mass spectrometry
- relative retention time on HPLC
- LC-MS
- peptide mapping
- amino acid analysis
- NMR spectroscopy
- bioactivity
"Orthogonal" means the methods rely on different principles. Mass spectrometry measures mass, while HPLC retention reflects chemical behavior such as hydrophobicity. Two methods that fail in different ways are much less likely to both be fooled. The EMA guideline adds that the chosen tests must be able to "unambiguously confirm the sequence" [2].
Learn more in Mass Spectrometry for Peptides.
Purity Testing: How Much Is the Target vs. Impurities?
What it answers
Purity testing estimates what proportion of the material is the target peptide, compared with other substances, especially peptide-related impurities.
What kinds of impurities?
EMA describes purity as "one of the most important critical quality attributes" for synthetic peptides, and groups impurities into two families [2]:
Peptide-related impurities, which contain parts of the peptide sequence:
- Deletion sequences: one or more amino acids missing, from incomplete coupling or deprotection steps
- Truncated sequences: shortened chains, for example capped fragments
- Insertion sequences: an amino acid added more than once
- Stereoisomers: variants containing the wrong mirror-image form of an amino acid
- Degradation products: from oxidation, deamidation, hydrolysis, and other reactions
- High molecular weight impurities: dimers, oligomers, and aggregates
Non-peptide impurities: process reagents and by-products, residual solvents, and elemental impurities [2].
A 2014 review of related impurities in peptide medicines describes similar categories and notes that impurities can even distort early research results, potentially leading to erroneous conclusions [3].
How it is measured
Purity is usually measured by liquid chromatography (HPLC), reported as the target peak's share of total peak area. Because some impurities can co-elute with the main peak, additional independent methods may be needed [2]. See HPLC Testing Explained.
Quantity Testing: How Much Peptide Is Actually There?
What it answers
Quantity testing, called assay or content, measures the amount of peptide present in a given amount of material.
How it is done
EMA lists several approaches for assay/content of synthetic peptides [2]:
- liquid chromatography against a reference standard (often the same method used for purity)
- amino acid analysis, which breaks the peptide down and measures its amino acids
- nitrogen analysis (Kjeldahl method)
- quantitative NMR (qNMR)
- elemental analysis
A reference standard is a well-characterized material of known quality used for comparison. ICH Q2(R2) defines reference materials as suitably characterized, sufficiently homogeneous, and stable [1].
Why purity is not the same as quantity
A lyophilized (freeze-dried) peptide powder is rarely 100% peptide by weight. EMA guidance highlights two main reasons [2]:
- Counter-ions (salts). Synthetic peptides generally carry counter-ions. Acetate is usually used, though trifluoroacetate (TFA) and chloride are also possible. The type and amount should be controlled because they can affect a peptide's properties.
- Water. Peptides are often very hygroscopic, meaning they absorb moisture from the air, so water content is tested separately.
EMA also notes that assay limits determined by liquid chromatography are expressed on a counter-ion-free, anhydrous (water-free) basis unless otherwise justified [2]. The percentage of actual peptide in the powder is often called net peptide content.
Illustrative example (hypothetical numbers): Imagine a powder whose HPLC purity is 98%. If water and counter-ions together make up 20% of its weight, then roughly 80% of the powder is peptide material, and only 98% of that is the target peptide. So less than 80% of the weight is the intended peptide, even though the purity result looks excellent.
Identity vs. Purity vs. Quantity Testing: Side-by-Side
| Identity | Purity | Quantity (assay/content) | |
|---|---|---|---|
| Question | Is it the right molecule? | What share is the target vs. impurities? | How much peptide is present? |
| Typical methods | MS, LC-MS, retention time, peptide mapping, amino acid analysis, NMR [2] | HPLC (UV), sometimes with additional orthogonal methods [2] | HPLC vs. reference standard, amino acid analysis, nitrogen analysis, qNMR [2] |
| Typical result | Conforms / does not conform, or expected vs. observed mass | Area % of main peak, plus individual impurities | Percentage or amount (e.g., mg per vial) |
| Common mistake | Assuming high purity proves identity | Assuming purity means peptide weight | Ignoring water and counter-ions |
What About Potency?
Potency is a quantitative measure of biological activity [4]. For many biotechnological products it is a core test [4]. For synthetic peptides, EMA states that a biological assay is generally not required for release and stability testing, though it may be needed in certain cases depending on the mechanism of action [2].
Other Tests on the Same Report
Identity, purity, and quantity are the core. A full specification for a synthetic peptide may also include appearance, residual solvents, elemental impurities, bacterial endotoxins, and microbiological purity [2]. To see how all of these appear together on one document, read What Is a Certificate of Analysis (COA)?.
Regulatory Status
The frameworks cited here come from ICH guidelines and from the EMA, which applies to medicinal products in the European Union. Other jurisdictions apply their own requirements, which may differ in detail. Materials not intended as medicinal products may not be tested to these standards at all. See Research-Grade vs. Pharmaceutical-Grade. Regulatory status varies by jurisdiction and may change over time. Consult the relevant regulatory authority for current information.
Frequently Asked Questions
What is the difference between peptide purity and peptide content?
Purity is the share of detected material that is the target peptide versus related impurities. Content (assay) is how much peptide is actually present, which also accounts for water and counter-ions [2].
Can a peptide be pure but wrong?
In principle, yes. A single large HPLC peak shows that one component dominates, not which component it is. This is why identity testing with orthogonal methods is recommended [2].
What is net peptide content?
It is the proportion of a material's weight that is actually peptide, as opposed to water, counter-ions, and other non-peptide components. Assay methods such as amino acid analysis or HPLC against a reference standard are used to determine it [2].
What are orthogonal methods?
Independent methods based on different scientific principles, such as mass spectrometry and HPLC retention time, used together so that one can catch what the other might miss [1][2].
Why is TFA mentioned in peptide testing?
Trifluoroacetate can remain as a counter-ion from synthesis or purification, so its content may be controlled and reported [2][3].
For a full walkthrough of reading these results, see How to Read a Peptide Lab Report and Common Peptide Quality Misconceptions.
References
- ICH. Q2(R2): Validation of Analytical Procedures (2023), Table 1 and Glossary. https://database.ich.org/sites/default/files/ICH_Q2%28R2%29_Guideline_2023_1130.pdf ↗
- European Medicines Agency. Guideline on the Development and Manufacture of Synthetic Peptides (EMA/CHMP/CVMP/QWP/367182/2025), sections 4.3–4.5. https://www.ema.europa.eu/en/development-manufacture-synthetic-peptides-scientific-guideline ↗
- D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2–30. https://doi.org/10.1016/j.jpba.2014.06.012 ↗
- ICH. Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products (Glossary). https://database.ich.org/sites/default/files/Q6B%20Guideline.pdf ↗
Educational disclaimer: This article is for general educational purposes only. It is not medical, legal, or regulatory advice, and it does not recommend or evaluate any product or supplier. For health questions, consult a qualified healthcare professional. For regulatory questions, consult the relevant regulatory authority in your jurisdiction.